<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716128</url>
  </required_header>
  <id_info>
    <org_study_id>H-17040409</org_study_id>
    <nct_id>NCT03716128</nct_id>
  </id_info>
  <brief_title>Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function</brief_title>
  <official_title>Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ditte Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to

        1. To describe the bone morphology in patients with reduced renal function and high or low
           parathyroid hormone (PTH) respectively.

        2. To investigate if the non-invasive method 18-Fluoride Positron Emission Tomography
           (18F-PET) can describe the bone turnover and reflect the bone histomorphologic changes

        3. To investigate if non-oxidized PTH reflects bone turnover
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with reduced renal function and suspected high turnover or low turnover bone disease
      are recruited.

      A bone biopsy and a 18F-PET scan are performed and it is investigated if the 18F-PET can
      discriminate high turnover from low turnover bone disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Can 18F-PET-CT describe bone formation rate?</measure>
    <time_frame>The bone biopsy and 18F-PET will be performed during two month for each participant</time_frame>
    <description>The ROC curve for 18F uptake by bone measured as bone plasma clearance (ki) to descriminate between high and low bone turnover measured as bone formation rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Can non-oxidized PTH describe bone formation rate?</measure>
    <time_frame>Blood sample and bone biopsy will be performed during two month for each participant</time_frame>
    <description>The relation between non-oxidized PTH in ng/L and bone turnover in bone biopsy described as bone formation rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Can 18F-PET-CT describe mineral apposition rate?</measure>
    <time_frame>The bone biopsy and 18F-PET will be performed during two month for each participant</time_frame>
    <description>The ROC curve for 18F uptake by bone measured as bone plasma clearance (ki) to descriminate between high and low bone turnover measured as mineral apposition rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Can non-oxidized PTH describe mineral apposition rate?</measure>
    <time_frame>Blood sample and bone biopsy will be performed during two month for each participant</time_frame>
    <description>The relation between non-oxidized PTH in ng/L and bone turnover in bone biopsy described as mineral apposition rate</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Low turnover bone disease</arm_group_label>
    <description>PTH&lt;150 pg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High turnover bone disease</arm_group_label>
    <description>PTH&gt;300 pg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <description>Patients under examination for prostate cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-PET</intervention_name>
    <description>Bone biopsy and 18F-PET</description>
    <arm_group_label>High turnover bone disease</arm_group_label>
    <arm_group_label>Low turnover bone disease</arm_group_label>
    <arm_group_label>Normal renal function</arm_group_label>
    <other_name>Bone biopsy</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone Biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under investigation for prostate cancer are recruited as bone healthy controls
        Patients with reduced renal function and suspected high or low bone turnover are recruited
        for bone biopsy, blood and urin samples and 18F-PET scan
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with reduced renal function:

        Inclusion Criteria:

        -≥ 18 years

          -  estimated Glomerular Filtration Rate (eGFR) ≤ 20 ml/min/1,73m2

          -  PTH &lt; 150 pg/ml or PTH &gt; 300 pg/ml

        Exclusion Criteria:

          -  ongoing malignancy

          -  Allergy towards tetracyclin

          -  Pregnancy

        Control Group:

        Inclusion Criteria:

        -≥ 18 years

          -  eGFR &gt;= 60 ml/min

          -  under examination for c prostata

          -  Prostatic Specific Antigen (PSA) total &lt;40 µg/l

        Exclusion:

          -  Former kidney disease

          -  ionized calcium or PTH outside normal range

          -  Known metabolic bone disease

          -  treatment with anticoagulants

          -  Disturbed thrombosis and hemostasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ditte Hansen, PhD</last_name>
    <phone>+4538683868</phone>
    <email>ditte.hansen.04@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ditte Hansen, PhD</last_name>
      <phone>+4538683868</phone>
      <email>ditte.hansen.04@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Ditte Hansen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

